Investor Presentaiton

Company overview Financial review 2022 priorities Appendix References Entresto® +33% cc, growing strongly across geographies Sales evolution USD m, % cc Ex-US US 00 8 +33% 7 1,125 6 886 577 5 481 548 405 Q2 2021 Q2 2022 2 4 US weekly NBRx1 New-to-brand prescriptions (000) 03/20 05/20 07/20 09/20 11/20 01/21 03/21 05/21 07/21 09/21 11/21 01/22 03/22 05/22 07/22 1 GROWTH C Entresto AZ K&K L Strong quarter performance " Worldwide >7m patients treated, US >1m TRX US growing in hospitals, cardiology, primary care¹ Europe strong demand growth Asia HTN driving growth Confident in future growth ■ Only 1/3 of addressable HF population treated in G72 Strong profile in clinical and RW settings in HF3,4 Guidelines drive 1st choice in HFrEF and expand support in HFPEF w/LVEF < normal 5 HTN: high unmet need in Asia See last slide for references TRX Total Prescriptions NBRX-New-to-brand Prescriptions RW Real world HFrEF-heart failure with reduced ejection fraction HFPEF-heart failure with preserved ejection fraction HTN - Hypertension LVEF - left ventricular ejection fraction 9 Investor Relations | Q2 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation